ARTICLE | Deals
Insilico caps year of deals by opening its computational platforms to pharmas’ in-house teams
Insilico is getting pharmas behind the wheel of its target, compound discovery tech
December 23, 2020 11:41 PM UTC
Coming off a string of deals to discover targets and compounds on its partners’ behalf, Insilico Medicine has launched versions of its platforms that pharmas can use themselves.
This year, Insilico Medicine Inc. made its molecular target and small molecule discovery platforms, respectively dubbed Pandaomics and Chemistry42, available as software that drug developers can adopt in-house. ...